` 4507 (Shionogi & Co Ltd) vs Nikkei 225 Comparison - Alpha Spread

4507
vs
Nikkei 225

Over the past 12 months, has significantly outperformed Nikkei 225, delivering a return of 20% compared to the Nikkei 225's 2% drop.

Stocks Performance
4507 vs Nikkei 225

Loading
4507
Nikkei 225
Add Stock

Performance Gap
4507 vs Nikkei 225

Loading

Over the past 12 months, has outperformed Nikkei 225 by 22.6%.

4507
Nikkei 225
Difference
www.alphaspread.com

Performance By Year
4507 vs Nikkei 225

Loading
4507
Nikkei 225
Add Stock

Competitors Performance
Shionogi & Co Ltd vs Peers

Nikkei 225
4507
LLY
JNJ
NOVO B
ROG
Add Stock

Shionogi & Co Ltd
Glance View

Market Cap
2.1T JPY
Industry
Pharmaceuticals

In the bustling landscape of pharmaceuticals, Shionogi & Co., Ltd. emerges as a distinguished player with a rich legacy rooted in over a century of innovation and meticulous craftsmanship. Founded in 1878, this Japanese pharmaceutical stalwart has strategically steered its trajectory toward addressing unmet medical needs through research-driven innovation. Shionogi's core strength lies in its research and development capabilities, focusing predominantly on infectious diseases, pain therapeutics, and chronic conditions such as cardiovascular diseases and diabetes. This dedication is evident in their robust pipeline and successful launch of drugs like Fetroja—an antibiotic that fights resistant bacterial infections—and Xofluza, a novel anti-influenza medication. By continually investing in and prioritizing R&D, Shionogi ensures a steady output of groundbreaking treatments that not only embody therapeutic efficacy but also meet stringent safety standards. Financially, Shionogi operates through a strategic blend of innovative product sales and lucrative licensing agreements. As its proprietary medications penetrate global markets, the revenue stream flowing from these products fortifies the company’s economic foundation. Notably, Shionogi nurtures collaborative alliances with international pharmaceutical giants, enhancing its global outreach through mutual licensing agreements and shared drug development initiatives. These alliances not only expand the availability of its drugs worldwide but also provide Shionogi with substantial royalty and milestone payments. Additionally, the company's foray into vaccine production has further diversified its portfolio, as it aims to leverage its technological prowess in response to global health challenges. This intricate balance of direct product sales and strategic alliances powerfully anchors Shionogi's financial stability while paving the way for future innovations.

Intrinsic Value
2 031.72 JPY
Overvaluation 16%
Intrinsic Value
Price
S
Back to Top